Poll: Vote on the Top Gynecologic and GI Cancer Abstracts/Topics to Watch at ESMO 2025

As the 2025 ESMO Congress in Berlin continues to inch closer, the excitement ahead of the meeting’s first sessions on October 17 continues to build. Late-breaking abstracts (LBAs) are again set to potentially impact clinical practice, and evolving thematic tracks will highlight the newest strategies for delivering precision, durability, and equity in gynecologic and gastrointestinal (GI) cancer management.

To tap into the perspectives of clinicians across settings, we are launching our latest round of community polls focused on the key abstracts, data, and topics in the gynecologic cancer and GI oncology spaces that will be shared during this year’s ESMO Congress. We invite medical, academic, and community oncologists to vote in four short polls—2 for gynecologic cancer and 2 for GI cancer. Voting is open now on X and LinkedIn through Thursday, October 9.

What Are the Top Abstracts to Watch in Gynecologic Cancer at the 2025 ESMO Congress?

The gynecologic oncology track at ESMO 2025 is poised to feature major updates across ovarian, endometrial, and cervical cancers. With novel combinations and maintenance strategies under study, this year’s abstracts may help redefine standards of care across multiple tumor types.

Poll 1 – Which gynecologic cancer abstract are you most anticipating at ESMO 2025?

Vote Now: X | LinkedIn

• LBA40: WES-derived Aneuploidy score (W-AS) identifies MMRd patients with reduced benefit from immunotherapy in endometrial cancer. Multi-omic analysis of the phase III AtTEnd/ENGOT-EN7 trial
• LBA44: Durvalumab + paclitaxel/carboplatin + bevacizumab followed by durvalumab, bevacizumab + olaparib maintenance in patients with newly diagnosed non-tBRCA-mutated advanced ovarian cancer: final overall survival from DUO-O/ENGOT-ov46/GOG-3025
• LBA45: ROSELLA (GOG3073, ENGOTov72, APGOT-OV10): relacorilant + nab-paclitaxel in the subgroup of patients with platinum-resistant ovarian cancer (PROC) previously exposed to a PARP inhibitor
• LBA38: Phase 3 study of camrelizumab plus famitinib versus platinum-based chemotherapy as first-line therapy for recurrent or metastatic cervical cancer

Poll 2 – Which gynecologic cancer subtype are you more interested in learning more about during ESMO 2025?

Vote Now: X | LinkedIn

• Ovarian Cancer
• Endometrial Cancer
• Cervical Cancer

How Will GI Oncology Be Spotlighted at the 2025 ESMO Congress?

The GI oncology program remains one of the most comprehensive and fast-evolving areas at ESMO, spanning breakthroughs in colorectal, gastric, hepatobiliary, and pancreatic cancers.

Poll 3 – Which GI cancer abstracts are you most anticipating at ESMO 2025?

Vote Now: X | LinkedIn

• LBA81: Final overall survival (OS) and the association of pathological outcomes with event-free survival (EFS) in MATTERHORN: A randomised, phase III study of durvalumab (D) plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric / gastroesophageal junction (G / GEJ) adenocarcinoma
• LBA79: Lenvatinib plus Pembrolizumab and Chemotherapy vs Pembrolizumab and Chemotherapy in Untreated Metastatic Esophageal Squamous Cell Carcinoma: The Randomized Phase 3 LEAP-014 Study
• LBA33: Circulating Tumor (ct) DNA-Guided Anti-EGFR Rechallenge Strategy in Metastatic Colorectal Cancer (mCRC): Final results of the phase II randomized CITRIC trial
• LBA32: Panitumumab retreatment followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA (ctDNA): Final results of the randomized PARERE trial by GONO

Poll 4 – Which GI cancer subtype is driving the most interest ahead of ESMO 2025?

Vote Now: X | LinkedIn

• Gastric/GEJ
• Pancreatic
• CRC
• HCC

Join the Conversation

These polls are designed to give the oncology community a voice in highlighting the most relevant and practice-shaping updates in gynecologic and GI cancer ahead of ESMO 2025. By voting, you’ll help reflect the priorities of clinicians across academic centers, community hospitals, and private practice settings.

The polls are now live on X and LinkedIn, and voting will remain open until Thursday, October 9. Join the discussion, share with colleagues, and check back at the end of the week to see which abstracts and themes your peers are most excited about.